Document is current
Any future updates will be listed below
-
Authors
Shi, Xiangguo
Li, Minhua
Liu, Zian
Tiessen, Jonathan
Li, Yuan
Zhou, Jing
Zhu, Yudan
Mahesula, Swetha
Ding, Qing
Tan, Lin
Feng, Mengdie https://orcid.org/0009-0006-4804-9761
Kageyama, Yuki https://orcid.org/0000-0002-0564-2227
Hara, Yusuke
Tao, Jacob J. https://orcid.org/0000-0003-2772-137X
Luo, Xuan
Patras, Kathryn A. https://orcid.org/0000-0003-2631-8810
Lorenzi, Philip L. https://orcid.org/0000-0003-0385-7774
Huang, Suming https://orcid.org/0000-0002-4788-2085
Stevens, Alexandra M.
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Issa, Ghayas C. https://orcid.org/0000-0002-4339-8683
Samee, Md. Abul Hassan https://orcid.org/0000-0002-7472-1156
Agathocleous, Michalis https://orcid.org/0000-0002-3427-1023
Nakada, Daisuke https://orcid.org/0000-0001-6010-7094
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA255813, P01CA265748, R01CA193235, P50CA100632, R01CA237291, R01CA260729, R01CA264932)
National Heart and Lung Institute (R01HL165145)
Leukemia and Lymphoma Society
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 26 February 2025
First Online: 18 March 2025
Competing interests
: K.T. received consultancy fees from Symbio Pharmaceuticals, honoraria from Mission Bio, Otsuka, and Illumina, and research funding from Onconova, ASTEX, and Jazz pharmaceuticals. G.C.I. received consultancy or advisory role fees from Novartis, Kura Oncology, Syndax Pharmaceuticals, Abbvie, Sanofi and NuProbe and received research funding from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology, Astex, NuProbe, and received research funding from Break Through Cancer. The remaining authors declare no competing interests.
